The influence of carrier protein on the immunogenicity of simultaneously administered conjugate vaccines in infants

Vaccine

Volumn 27, Issue 11, 2009, Pages 1674-1679

  Pöllabauer, Eva Maria ^a   Petermann, Robert ^a   Ehrlich, Hartmut J ^a  

^a BAXTER BIOSCIENCE   (Austria)

Author keywords

Meningococcal; Review; Vaccination

Indexed keywords

BACTERIUM ANTIBODY; CARRIER PROTEIN; DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TOXIN; DIPHTHERIA TOXOID CRM197; EPITOPE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; IMMUNOGLOBULIN G; MEASLES MUMPS RUBELLA VACCINE; MENINGOCOCCUS VACCINE; MENITORIX; ORAL POLIOMYELITIS VACCINE; OUTER MEMBRANE PROTEIN; PEDIACEL; PENTACEL; PERTUSSIS VACCINE; PNEUMOCOCCUS VACCINE; POLYRIBOSYLRIBITOL PHOSPHATE ANTIBODY; TETANUS TOXOID; TRIVAX AD; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN RECOGNITION; CLINICAL TRIAL; DRUG ANTIGENICITY; DRUG COMPETITION; DRUG CONJUGATION; DRUG FORMULATION; DRUG POTENTIATION; HUMAN; IMMUNOGENICITY; PREDICTION; PRIORITY JOURNAL; REVIEW; VACCINATION;

ANTIBODIES, BACTERIAL; CARRIER PROTEINS; EPITOPES; HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS VACCINES; HUMANS; INFANT; INFANT, NEWBORN; NEISSERIA MENINGITIDIS, SEROGROUP C; TETANUS TOXOID; VACCINES, CONJUGATE;

EID: 61349200781     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.01.005     Document Type: Review

References (52)

1. Clemens J., Brenner R., and Rao M. Interactions between PRP-T vaccine against Haemophilus influenzae type b and conventional infant vaccines. Lessons for future studies of simultaneous immunization and combined vaccines. Ann N Y Acad Sci 754 (1995) 255-266
2. Buttery J.P., Riddell A., McVernon J., Chantler T., Lane L., Bowen-Morris J., et al. Immunogenicity and safety of a combination pneumococcal-meningococcal vaccine in infants: a randomized controlled trial. JAMA 293 14 (2005) 1751-1758
3. Finn A., and Heath P. Conjugate vaccines. Arch Dis Child 90 7 (2005) 667-669
4. Pöllabauer E.M., Petermann R., and Ehrlich H.J. Group C meningococcal polysaccharide-tetanus toxoid conjugate vaccine: a meta-analysis of immunogenicity, safety and posology. Hum Vaccin 1 4 (2005) 131-139
5. Galizia E.P., and Heath P.T. Pneumococcal conjugate vaccines. A review. Minerva Med 98 2 (2007) 131-143
6. Makwana N., and Riordan F.A. Bacterial meningitis: the impact of vaccination. CNS Drugs 21 5 (2007) 355-366
7. Finn A. Bacterial polysaccharide-protein conjugate vaccines. Br Med Bull 70 (2004) 1-14
8. Dagan R., Eskola J., Leclerc C., and Leroy O. Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants. Infect Immun 66 5 (1998) 2093-2098
9. Dagan R., Goldblatt D., Maleckar J.R., Yaich M., and Eskola J. Reduction of antibody response to an 11-valent pneumococcal vaccine coadministered with a vaccine containing acellular pertussis components. Infect Immun 72 9 (2004) 5383-5391
10. Heath P.T., and McVernon J. The UK Hib vaccine experience. Arch Dis Child 86 6 (2002) 396-399
11. McVernon J., Andrews N., Slack M.P., and Ramsay M.E. Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis. Lancet 361 9368 (2003) 1521-1523
12. 197 conjugates. Expert Rev Vaccines 7 1 (2008) 97-115
13. Trotter C.L., Ramsay M.E., and Slack M.P. Rising incidence of Haemophilus influenzae type b disease in England and Wales indicates a need for a second catch-up vaccination campaign. Commun Dis Public Health 6 1 (2003) 55-58
14. Pollard A.J. New combination vaccines still need a boost. Arch Dis Child 92 1 (2007) 1-2
15. Eskola J., Olander R.M., Hovi T., Litmanen L., Peltola S., and Kayhty H. Randomised trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine. Lancet 348 9043 (1996) 1688-1692
16. Pichichero M.E., Latiolais T., Bernstein D.I., Hosbach P., Christian E., Vidor E., et al. Vaccine antigen interactions after a combination diphtheria-tetanus toxoid-acellular pertussis/purified capsular polysaccharide of Haemophilus influenzae type b-tetanus toxoid vaccine in two-, four- and six-month-old infants. Pediatr Infect Dis J 16 9 (1997) 863-870
17. Schmitt H.J., Zepp F., Müschenborn S., Sümenicht G., Schuind A., Beutel K., et al. Immunogenicity and reactogenicity of a Haemophilus influenzae type b tetanus conjugate vaccine when administered separately or mixed with concomitant diphtheria-tetanus-toxoid and acellular pertussis vaccine for primary and for booster immunizations. Eur J Pediatr 157 3 (1998) 208-214
18. Kitchin N.R., Southern J., Morris R., Hemme F., Thomas S., Watson M.W., et al. Evaluation of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b vaccine given concurrently with meningococcal group C conjugate vaccine at 2, 3 and 4 months of age. Arch Dis Child 92 1 (2007) 11-16
19. Bell F., Heath P., Shackley F., MacLennan J., Shearstone N., Diggle L., et al. Effect of combination with an acellular pertussis, diphtheria, tetanus vaccine on antibody response to Hib vaccine (PRP-T). Vaccine 16 6 (1998) 637-642
20. Eskola J., Ward J., Dagan R., Goldblatt D., Zepp F., and Siegrist C.A. Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis. Lancet 354 9195 (1999) 2063-2068
21. Decker M.D., and Edwards K.M. Combination vaccines: problems and promise. J Pediatr 137 3 (2000) 291-295
22. Daum R.S., Zenko C.E., Given G.Z., Ballanco G.A., Parikh H., and Germino K. Magnitude of interference after diphtheria-tetanus toxoids-acellular pertussis/Haemophilus influenzae type b capsular polysaccharide-tetanus vaccination is related to the number of doses administered. J Infect Dis 184 10 (2001) 1293-1299
23. Poolman J., Kaufhold A., De Grave D., and Goldblatt D. Clinical relevance of lower Hib response in DTPa-based combination vaccines. Vaccine 19 17-19 (2001) 2280-2285
24. Johnson N.G., Ruggeberg J.U., Balfour G.F., Lee Y.C., Liddy H., Irving D., et al. Haemophilus influenzae type b reemergence after combination immunization. Emerg Infect Dis 12 6 (2006) 937-941
25. Rennels M.B., Englund J.A., Bernstein D.I., Losonsky G.A., Anderson E.L., Pichichero M.E., et al. Diminution of the anti-polyribosylribitol phosphate response to a combined diphtheria-tetanus-acellular pertussis/Haemophilus influenzae type b vaccine by concurrent inactivated poliovirus vaccination. Pediatr Infect Dis J 19 5 (2000) 417-423
26. Carlsson R.M., Claesson B.A., Kayhty H., Selstam U., and Iwarson S. Studies on a Hib-tetanus toxoid conjugate vaccine: effects of co-administered tetanus toxoid vaccine, of administration route and of combined administration with an inactivated polio vaccine. Vaccine 18 5-6 (1999) 468-478
27. Oosterhuis-Kafeja F., Beutels P., and Van Damme P. Immunogenicity, efficacy, safety and effectiveness of pneumococcal conjugate vaccines (1998-2006). Vaccine 25 12 (2007) 2194-2212
28. Decker M.D., Edwards K.M., Bradley R., and Palmer P. Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines. J Pediatr 120 2 Pt 1 (1992) 184-189
29. Ada G., and Isaacs D. Carbohydrate-protein conjugate vaccines. Clin Microbiol Infect 9 2 (2003) 79-85
30. Scott D., Ruckle J., Dar M., Baker S., Kondoh H., and Lockhart S. Phase 1 trial of 13-valent pneumococcal conjugate vaccine in Japanese adults. Pediatr Int 50 3 (2008) 295-299
31. Richmond P., Borrow R., Findlow J., Martin S., Thornton C., Cartwright K., et al. Evaluation of de-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: reactogenicity, immunogenicity, immunologic priming, and bactericidal activity against O-acetylated and de-O-acetylated serogroup C strains. Infect Immun 69 4 (2001) 2378-2382
32. Kitchin N., Southern J., Morris R., Hemme F., Cartwright K., Watson M., et al. A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age. Vaccine 24 18 (2006) 3964-3970
33. Southern J., Crowley-Luke A., Borrow R., Andrews N., and Miller E. Immunogenicity of one, two or three doses of a meningococcal C conjugate vaccine conjugated to tetanus toxoid, given as a three-dose primary vaccination course in UK infants at 2, 3 and 4 months of age with acellular pertussis-containing DTP/Hib vaccine. Vaccine 24 2 (2006) 215-219
34. Tejedor J.C., Moro M., Ruiz-Contreras J., Castro J., Gómez-Campderá J.A., Navarro M.L., et al. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine. Pediatr Infect Dis J 25 8 (2006) 713-720
35. Miller E, Southern J, Andrews N, Crowley-Luke A, Hudson M, Balmer P, et al. Immunogenicity and booster response after infant vaccination with a reduced schedule of 7-valent pneumococcal conjugate and one of three monovalent meningococcal group C conjugate vaccines. Presented at the 25th Annual Meeting of the European Society for Paediatric Infectious Diseases, Porto, Portugal, May 2-4; 2007.
36. Schmitt H.J., Maechler G., Habermehl P., Knuf M., Saenger R., Begg N., et al. Immunogenicity, reactogenicity, and immune memory after primary vaccination with a novel Haemophilus influenzae-Neisseria meningitidis serogroup C conjugate vaccine. Clin Vaccine Immunol 14 4 (2007) 426-434
37. Gatchalian S., Palestroque E., De Vleeschauwer I., Han H.H., Poolman J., Schuerman L., et al. The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components. Int J Infect Dis 12 3 (2008) 278-288
38. English M., MacLennan J.M., Bowen-Morris J.M., Deeks J., Boardman M., Brown K., et al. A randomised, double-blind, controlled trial of the immunogenicity and tolerability of a meningococcal group C conjugate vaccine in young British infants. Vaccine 19 9-10 (2000) 1232-1238
39. Granoff D.M., Rathore M.H., Holmes S.J., Granoff P.D., and Lucas A.H. Effect of immunity to the carrier protein on antibody responses to Haemophilus influenzae type b conjugate vaccines. Vaccine 11 Suppl. 1 (1993) S46-51
40. Castillo de Febres O., Decker M.D., Estopinan M., Bordones G., and Edwards K.M. Enhanced antibody response in Venezuelan infants immunized with Haemophilus influenzae type b-tetanus toxoid conjugate vaccine. Pediatr Infect Dis J 13 7 (1994) 635-639
41. Granoff D.M., Holmes S.J., Belshe R.B., Osterholm M.T., McHugh J.E., and Anderson E.L. Effect of carrier protein priming on antibody responses to Haemophilus influenzae type b conjugate vaccines in infants. JAMA 272 14 (1994) 1116-1121
42. Kurikka S. Priming with diphtheria-tetanus-pertussis vaccine enhances the response to the Haemophilus influenzae type b tetanus conjugate vaccine in infancy. Vaccine 14 13 (1996) 1239-1242
43. Goldblatt D., Southern J., Ashton L., Richmond P., Burbidge P., Tasevska J., et al. Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers. Pediatr Infect Dis J 25 4 (2006) 312-319
44. Tejedor J.C., Moro M., Ruiz-Contreras J., Castro J., Gómez-Campderá J.A., Navarro M.L., et al. Immunogenicity and reactogenicity of primary immunization with a novel combined Haemophilus influenzae Type b and Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine coadministered with a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus vaccine at 2, 4 and 6 months. Pediatr Infect Dis J 26 1 (2007) 1-7
45. Insel R.A. Potential alterations in immunogenicity by combining or simultaneously administering vaccine components. Ann N Y Acad Sci 754 (1995) 35-67
46. Herzenberg L.A., and Tokuhisa T. Carrier-priming leads to hapten-specific suppression. Nature 285 5767 (1980) 664-667
47. Schutze M.P., Deriaud E., Przewlocki G., and LeClerc C. Carrier-induced epitopic suppression is initiated through clonal dominance. J Immunol 142 8 (1989) 2635-2640
48. Renjifo X., Wolf S., Pastoret P.P., Bazin H., Urbain J., Leo O., et al. Carrier-induced, hapten-specific suppression: a problem of antigen presentation?. J Immunol 161 2 (1998) 702-706
49. Herzenberg L.A., and Tokuhisa T. Epitope-specific regulation. I. Carrier-specific induction of suppression for IgG anti-hapten antibody responses. J Exp Med 155 6 (1982) 1730-1740
50. Peeters C.C., Tenbergen-Meekes A.M., Poolman J.T., Beurret M., Zegers B.J., and Rijkers G.T. Effect of carrier priming on immunogenicity of saccharide-protein conjugate vaccines. Infect Immun 59 10 (1991) 3504-3510
51. Di John D., Wasserman S.S., Torres J.R., Cortesia M.J., Murillo J., Losonsky G.A., et al. Effect of priming with carrier on response to conjugate vaccine. Lancet 2 8677 (1989) 1415-1418
52. Redhead K., Sesardic D., Yost S.E., Attwell A.M., Watkins J., Hoy C.S., et al. Interaction of Haemophilus influenzae type b conjugate vaccines with diphtheria-tetanus-pertussis vaccine in control tests. Vaccine 12 15 (1994) 1460-1466